Immix Biopharma, Inc. (IMMX) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Immix Biopharma, Inc. (IMMX) Earnings Overview
As of June 12, 2026, Immix Biopharma, Inc. (IMMX) reported trailing twelve-month net income of -$35M, reflecting -17.1% year-over-year growth. The company earned $-0.91 per diluted share over the past four quarters.
Looking at the long-term picture, IMMX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$972,811 in fiscal 2019.
Immix Biopharma, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CABA (-$175M net income), KYMR (-$315M net income, -794.4% margin), IMVT (-$506M net income), IMMX has comparable earnings metrics. Compare IMMX vs CABA →
IMMX Earnings vs Peers
Earnings metrics vs comparable public companies
IMMX Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$29M | -36.2% | -$27M | $-0.89 | - | - |
| 2024 | -$22M | -40.1% | -$23M | $-0.76 | - | - |
| 2023 | -$15M | -87.4% | -$16M | $-0.89 | - | - |
| 2022 | -$8M | +66.2% | -$8M | $-0.59 | - | - |
| 2021 | -$24M | -2024.3% | -$1M | $-6.64 | - | - |
| 2020 | -$1M | -18.0% | $-453,852 | $-0.15 | - | - |
| 2019 | $-972,811 | - | $-842,499 | $-0.29 | - | - |
Download Data
Export IMMX earnings history in CSV or JSON format
Free sign-in required to download data
What if you invested $1,000 in IMMX back in 2019?
Total return with dividends reinvested · 7+ years of data
Calculate ReturnsHow much would $100/month in IMMX be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs IMMX Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationIMMX vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowIMMX — Frequently Asked Questions
Quick answers to the most common questions about buying IMMX stock.
What is IMMX earnings per share (EPS)?
IMMX trailing twelve-month (TTM) diluted EPS is $-0.91, reflecting -17.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Immix Biopharma, Inc.'s net income?
Immix Biopharma, Inc. (IMMX) trailing twelve-month net income is $-35M as of 2025. Earnings declined -17.1% year-over-year.
Is IMMX profitable?
IMMX is not currently profitable on a TTM basis, reporting a net loss of $-35M. Net margin is N/A. Investors should monitor for a return to profitability.
What is IMMX's earnings growth rate?
IMMX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are IMMX's profit margins?
Immix Biopharma, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -55.0%.
Is IMMX growing earnings?
IMMX earnings are declining — EPS fell -17.1% year-over-year. TTM net income dropped to $-35M. This contrasts with the 5-year CAGR of N/A.
What was IMMX's best earnings year?
Immix Biopharma, Inc.'s highest annual net income on record is $-972811.00, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were IMMX's earnings last quarter?
IMMX's most recent reported quarter was Q1 2026. Net income was $-10M with diluted EPS of $-0.18. For a full breakdown of all quarters, see the quarterly earnings table on this page.